Canine epilepsy as a translational model?

Epilepsia

Volumn 54, Issue 4, 2013, Pages 571-579

  Potschka, Heidrun ^a   Fischer, Andrea ^a   Von Rüden, Eva Lotta ^a   Hülsmeyer, Velia ^a   Baumgärtner, Wolfgang ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Animal model; Antiepileptic drug; Drug resistance; Epilepsy; Genetic; Seizure

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; FELBAMATE; GABAPENTIN; IMEPITOIN; LAMOTRIGINE; PHENOBARBITAL; POTASSIUM BROMIDE; PREGABALIN; TOPIRAMATE; ZONISAMIDE;

ADD ON THERAPY; BREEDING; COMORBIDITY; DOG; DRUG COST; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; GENETIC ASSOCIATION; MYOCLONUS EPILEPSY; NERVOUS SYSTEM DEVELOPMENT; NEURONAL CEROID LIPOFUSCINOSIS; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ANTICONVULSANTS; BRAIN; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; EPILEPSIES, MYOCLONIC; EPILEPSY; SEIZURES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84875831584     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12138     Document Type: Review

References (76)

1. Abitbol M, Thibaud JL, Olby NJ, Hitte C, Puech JP, Maurer M, Pilot-Storck F, Hedan B, Dreano S, Brahimi S, Delattre D, Andre C, Gray F, Delisle F, Caillaud C, Bernex F, Panthier JJ, Aubin-Houzelstein G, Blot S, Tiret L,. (2010) A canine Arylsulfatase G (ARSG) mutation leading to a sulfatase deficiency is associated with neuronal ceroid lipofuscinosis. Proc Natl Acad Sci USA 107: 14775-14780.
2. Arrol L, Penderis J, Garosi L, Cripps P, Gutierrez-Quintana R, Goncalves R,. (2012) Aetiology and long-term outcome of juvenile epilepsy in 136 dogs. Vet Rec 170: 335.
3. Berendt M, Gram L,. (1999) Epilepsy and seizure classification in 63 dogs: a reappraisal of veterinary epilepsy terminology. J Vet Intern Med 13: 14-20.
4. Beck H,. (2007) Plasticity of antiepileptic drug targets. Epilepsia 48 (Suppl. 1): 14-18.
5. Berendt M, Gullov CH, Fredholm M,. (2009) Focal epilepsy in the Belgian shepherd: evidence for simple Mendelian inheritance. J Small Anim Pract 50: 655-661.
6. Beyenburg S, Stavem K, Schmidt D,. (2010) Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 51: 7-26.
7. Bialer M, White HS,. (2010) Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov 9: 68-82.
8. Boothe DM, Dewey C, Carpenter DM,. (2012) Comparison of phenobarbital with bromide as a first-choice antiepileptic drug for treatment of epilepsy in dogs. J Am Vet Med Assoc 240: 1073-1083.
9. Brauer C, Kastner SB, Schenk HC, Tunsmeyer J, Tipold A,. (2011) Electroencephalographic recordings in dogs: prevention of muscle artifacts and evaluation of two activation techniques in healthy individuals. Res Vet Sci 90: 306-311.
10. Buckmaster PS, Smith MO, Buckmaster CL, LeCouteur RA, Dudek FE,. (2002) Absence of temporal lobe epilepsy pathology in dogs with medically intractable epilepsy. J Vet Intern Med 16: 95-99.
11. Bush WW, Barr CS, Darrin EW, Shofer FS, Vite CH, Steinberg SA,. (2002) Results of cerebrospinal fluid analysis, neurologic examination findings, and age at the onset of seizures as predictors for results of magnetic resonance imaging of the brain in dogs examined because of seizures: 115 cases (1992-2000). J Am Vet Med Assoc 220: 781-784.
12. Casal ML, Munuve RM, Janis MA, Werner P, Henthorn PS,. (2006) Epilepsy in Irish Wolfhounds. J Vet Intern Med 20: 131-135.
13. Chan EM, Bulman DE, Paterson AD, Turnbull J, Andermann E, Andermann F, Rouleau GA, Delgado-Escueta AV, Scherer SW, Minassian BA,. (2003a) Genetic mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22. J Med Genet 40: 671-675.
14. Chan EM, Young EJ, Ianzano L, Munteanu I, Zhao X, Christopoulos CC, Avanzini G, Elia M, Ackerley CA, Jovic NJ, Bohlega S, Andermann E, Rouleau GA, Delgado-Escueta AV, Minassian BA, Scherer SW,. (2003b) Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet 35: 125-127.
15. Chandler K,. (2006) Canine epilepsy: what can we learn from human seizure disorders? Vet J 172: 207-217.
16. Davis KA, Sturges BK, Vite CH, Ruedebusch V, Worrell G, Gardner AB, Leyde K, Sheffield WD, Litt B,. (2011) A novel implanted device to wirelessly record and analyze continuous intracranial canine EEG. Epilepsy Res 96: 116-122.
17. Dewey CW, Guiliano R, Boothe DM, Berg JM, Kortz GD, Joseph RJ, Budsberg SC,. (2004) Zonisamide therapy for refractory idiopathic epilepsy in dogs. J Am Anim Hosp Assoc 40: 285-291.
18. Dewey CW, Cerda-Gonzalez S, Levine JM, Badgley BL, Ducote JM, Silver GM, Cooper JJ, Packer RA, Lavely JA,. (2009) Pregabalin as an adjunct to phenobarbital, potassium bromide, or a combination of phenobarbital and potassium bromide for treatment of dogs with suspected idiopathic epilepsy. J Am Vet Med Assoc 235: 1442-1449.
19. Ekenstedt KJ, Patterson EE, Mickelson JR,. (2012) Canine epilepsy genetics. Mamm Genome 23: 28-39.
20. Farias FH, Zeng R, Johnson GS, Wininger FA, Taylor JF, Schnabel RD, McKay SD, Sanders DN, Lohi H, Seppala EH, Wade CM, Lindblad-Toh K, O'Brien DP, Katz ML,. (2011) A truncating mutation in ATP13A2 is responsible for adult-onset neuronal ceroid lipofuscinosis in Tibetan terriers. Neurobiol Dis 42: 468-474.
21. Frey HH, Loscher W,. (1985) Pharmacokinetics of anti-epileptic drugs in the dog: a review. J Vet Pharmacol Ther 8: 219-233.
22. Govendir M, Perkins M, Malik R,. (2005) Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent. Aust Vet J 83: 602-608.
23. Gredal H, Berendt M, Leifsson PS,. (2003) Progressive myoclonus epilepsy in a beagle. J Small Anim Pract 44: 511-514.
24. Gullov CH, Toft N, Baadsager MM, Berendt M,. (2011) Epilepsy in the Petit Basset Griffon Vendeen: prevalence, semiology, and clinical phenotype. J Vet Intern Med 25: 1372-1378.
25. Hulsmeyer V, Zimmermann R, Brauer C, Sauter-Louis C, Fischer A,. (2010) Epilepsy in Border Collies: clinical manifestation, outcome, and mode of inheritance. J Vet Intern Med 24: 171-178.
26. Jokinen TS, Metsahonkala L, Bergamasco L, Viitmaa R, Syrja P, Lohi H, Snellman M, Jeserevics J, Cizinauskas S,. (2007) Benign familial juvenile epilepsy in Lagotto Romagnolo dogs. J Vet Intern Med 21: 464-471.
27. Karlsson EK, Lindblad-Toh K,. (2008) Leader of the pack: gene mapping in dogs and other model organisms. Nat Rev Genet 9: 713-725.
28. Kluger EK, Malik R, Govendir M,. (2009) Veterinarians' preferences for anticonvulsant drugs for treating seizure disorders in dogs and cats. Aust Vet J 87: 445-449.
29. Koestner A,. (1989) Neuropathology of canine epilepsy. Probl Vet Med 1: 516-534.
30. Kousi M, Lehesjoki AE, Mole SE,. (2012) Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Hum Mutat 33: 42-63.
31. Kuwabara T, Hasegawa D, Kobayashi M, Fujita M, Orima H,. (2010) Clinical magnetic resonance volumetry of the hippocampus in 58 epileptic dogs. Vet Radiol Ultrasound 51: 485-490.
32. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshe SL, Perucca E, Wiebe S, French J,. (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51: 1069-1077.
33. Leppik IE, Patterson EN, Coles LD, Craft EM, Cloyd JC,. (2011) Canine status epilepticus: a translational platform for human therapeutic trials. Epilepsia 52 (Suppl. 8): 31-34.
34. Lohi H, Young EJ, Fitzmaurice SN, Rusbridge C, Chan EM, Vervoort M, Turnbull J, Zhao XC, Ianzano L, Paterson AD, Sutter NB, Ostrander EA, Andre C, Shelton GD, Ackerley CA, Scherer SW, Minassian BA,. (2005) Expanded repeat in canine epilepsy. Science 307: 81.
35. Loscher W,. (1997) Animal models of intractable epilepsy. Prog Neurobiol 53: 239-258.
36. Löscher W,. (2003) Pharmakologische Grundlagen zur Behandlung von Epilepsie bei Hund und Katze. Prakt Tierarzt 84: 574-586.
37. Loscher W,. (2005) Mechanisms of drug resistance. Epileptic Disord 7 (Suppl. 1): S3-S9.
38. Loscher W,. (2012) Strategies for antiepileptogenesis. In, Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, (Eds) Jasper's basic mechanisms of the epilepsies [Internet]. 4th ed. National Center for Biotechnology Information (US), Bethesda, MD, pp. 1055-1065.
39. Loscher W, Schmidt D,. (2011) Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 52: 657-678.
40. Loscher W, Schwartz-Porsche D, Frey HH, Schmidt D,. (1985) Evaluation of epileptic dogs as an animal model of human epilepsy. Arzneimittelforschung 35: 82-87.
41. Loscher W, Potschka H, Rieck S, Tipold A, Rundfeldt C,. (2004) Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures. Epilepsia 45: 1228-1239.
42. Mariscoli M, Jaggy A,. (1997) Clinical and electroencephalographic findings of inflammatory and infectious diseases of the central nervous system in dogs: a retrospective study. Zentralbl Veterinarmed B 44: 1-18.
43. Minassian BA,. (2001) Lafora's disease: towards a clinical, pathologic, and molecular synthesis. Pediatr Neurol 25: 21-29.
44. Morita T, Shimada A, Takeuchi T, Hikasa Y, Sawada M, Ohiwa S, Takahashi M, Kubo N, Shibahara T, Miyata H, Ohama E,. (2002) Cliniconeuropathologic findings of familial frontal lobe epilepsy in Shetland sheepdogs. Can J Vet Res 66: 35-41.
45. Munana KR, Zhang D, Patterson EE,. (2010) Placebo effect in canine epilepsy trials. J Vet Intern Med 24: 166-170.
46. Munana KR, Thomas WB, Inzana KD, Nettifee-Osborne JA, McLucas KJ, Olby NJ, Mariani CJ, Early PJ,. (2012) Evaluation of levetiracetam as adjunctive treatment for refractory canine epilepsy: a randomized, placebo-controlled, crossover trial. J Vet Intern Med 26: 341-348.
47. Nowend KL, Starr-Moss AN, Murphy KE,. (2011) The function of dog models in developing gene therapy strategies for human health. Mamm Genome 22: 476-485.
48. Pakozdy A, Leschnik M, Tichy AG, Thalhammer JG,. (2008) Retrospective clinical comparison of idiopathic versus symptomatic epilepsy in 240 dogs with seizures. Acta Vet Hung 56: 471-483.
49. Palmer AC,. (1972) Pathological changes in the brain associated with fits in dogs. Vet Rec 90: 167-173.
50. Pitkanen A, Lukasiuk K,. (2011) Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol 10: 173-186.
51. Platt SR, Adams V, Garosi LS, Abramson CJ, Penderis J, De Stefani A, Matiasek L,. (2006) Treatment with gabapentin of 11 dogs with refractory idiopathic epilepsy. Vet Rec 159: 881-884.
52. Podell M, Fenner WR, Powers JD,. (1995) Seizure classification in dogs from a nonreferral-based population. J Am Vet Med Assoc 206: 1721-1728.
53. Poma R, Ochi A, Cortez MA,. (2010) Absence seizures with myoclonic features in a juvenile Chihuahua dog. Epileptic Disord 12: 138-141.
54. Potschka H,. (2010) Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies? Epilepsia 51: 1333-1347.
55. Potschka H, Volk HA, Pekcec A,. (2009) Aktueller Stand und Trends in der Epilepsietherapie bei Hund und Katze. Tieraerztl Prax 37: 211-217.
56. Pugliatti M, Beghi E, Forsgren L, Ekman M, Sobocki P,. (2007) Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia 48: 2224-2233.
57. Ramachandran N, Girard JM, Turnbull J, Minassian BA,. (2009) The autosomal recessively inherited progressive myoclonus epilepsies and their genes. Epilepsia 50 (Suppl. 5): 29-36.
58. Rogawski MA, Johnson MR,. (2008) Intrinsic severity as a determinant of antiepileptic drug refractoriness. Epilepsy Curr 8: 127-130.
59. Rowell JL, McCarthy DO, Alvarez CE,. (2011) Dog models of naturally occurring cancer. Trends Mol Med 17: 380-388.
60. Schwartz M, Lamb CR, Brodbelt DC, Volk HA,. (2011) Canine intracranial neoplasia: clinical risk factors for development of epileptic seizures. J Small Anim Pract 52: 632-637.
61. Schwartz-Porsche D, Jurgens U,. (1991) Effectiveness of bromide in therapy resistant epilepsy of dogs. Tierarztl Prax 19: 395-401.
62. Schwartz-Porsche D, Löscher W, Frey HH,. (1985) Therapeutic efficacy of phenobarbital and primidone in canine epilepsy: a comparison. J Vet Pharmacol Ther 8: 113-119.
63. Seppala EH, Jokinen TS, Fukata M, Fukata Y, Webster MT, Karlsson EK, Kilpinen SK, Steffen F, Dietschi E, Leeb T, Eklund R, Zhao X, Rilstone JJ, Lindblad-Toh K, Minassian BA, Lohi H,. (2011) LGI2 truncation causes a remitting focal epilepsy in dogs. PLoS Genet 7: e1002194.
64. Seppala EH, Koskinen LL, Gullov CH, Jokinen P, Karlskov-Mortensen P, Bergamasco L, Baranowska Korberg I, Cizinauskas S, Oberbauer AM, Berendt M, Fredholm M, Lohi H,. (2012) Identification of a novel idiopathic epilepsy locus in Belgian Shepherd dogs. PLoS ONE 7: e33549.
65. Shihab N, Bowen J, Volk HA,. (2011) Behavioral changes in dogs associated with the development of idiopathic epilepsy. Epilepsy Behav 21: 160-167.
66. Smith PM, Talbot CE, Jeffery ND,. (2008) Findings on low-field cranial MR images in epileptic dogs that lack interictal neurological deficits. Vet J 176: 320-325.
67. Steinmetz S, Tipold A, Loscher W,. (2013) Epilepsy after head injury in dogs: a natural model of posttraumatic epilepsy. Epilepsia Jan 7 [Epub ahead of print].
68. Tatum WOT, Winters L, Gieron M, Passaro EA, Benbadis S, Ferreira J, Liporace J,. (2001) Outpatient seizure identification: results of 502 patients using computer-assisted ambulatory EEG. J Clin Neurophysiol 18: 14-19.
69. Thomas WB,. (2010) Idiopathic epilepsy in dogs and cats. Vet Clin North Am Small Anim Pract 40: 161-179.
70. Volk HA, Matiasek LA, Lujan Feliu-Pascual A, Platt SR, Chandler KE,. (2008) The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs. Vet J 176: 310-319.
71. von Klopmann T, Rambeck B, Tipold A,. (2007) Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs. J Small Anim Pract 48: 134-138.
72. von Ruden EL, Avemary J, Zellinger C, Algermissen D, Bock P, Beineke A, Baumgartner W, Stein VM, Tipold A, Potschka H,. (2012) Distemper virus encephalitis exerts detrimental effects on hippocampal neurogenesis. Neuropathol Appl Neurobiol 38: 426-442.
73. Weissl J, Hulsmeyer V, Brauer C, Tipold A, Koskinen LL, Kyostila K, Lohi H, Sauter-Louis C, Wolf M, Fischer A,. (2012) Disease progression and treatment response of idiopathic epilepsy in Australian Shepherd dogs. J Vet Intern Med 26: 116-125.
74. Wohlke A, Philipp U, Bock P, Beineke A, Lichtner P, Meitinger T, Distl O,. (2011) A one base pair deletion in the canine ATP13A2 gene causes exon skipping and late-onset neuronal ceroid lipofuscinosis in the Tibetan terrier. PLoS Genet 7: e1002304.
75. Wolff CA, Holmes SP, Young BD, Chen AV, Kent M, Platt SR, Savage MY, Schatzberg SJ, Fosgate GT, Levine JM,. (2012) Magnetic resonance imaging for the differentiation of neoplastic, inflammatory, and cerebrovascular brain disease in dogs. J Vet Intern Med 26: 589-597.
76. Wong IC, Lhatoo SD,. (2000) Adverse reactions to new anticonvulsant drugs. Drug Saf 23: 35-56.